Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 301-037-8 | CAS number: 93980-59-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Skin sensitisation in vivo (OECD 429, LLNA): not sensitising
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 Nov - 19 Dec 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- adopted in 2010
- Deviations:
- yes
- Remarks:
- No data on range finding study are given in the report.
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA): BrdU-ELISA
- Species:
- mouse
- Strain:
- CBA
- Remarks:
- /N, SPF
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Central Lab. Animal Inc., Republic of Korea
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 9 weeks
- Weight at study initiation: 17.9 - 22.2 g (prior to dose range finding study)
- Housing: 2 - 3 animals per cage in polysulfone cages
- Diet: Pelleted rodent chow (Teklad Certified Irradiated Global 18% Protein Rodent Diet 2918C, Envigo RMS, Inc., U.S.A.), ad libitum
- Water: public tap water, ad libitum (analysis was performed)
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.8 - 24.7
- Humidity (%): 51.6 - 62.7
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12/12 - Vehicle:
- methyl ethyl ketone
- Remarks:
- (MEK)
- Concentration:
- 2.5, 5 and 10%
- No. of animals per dose:
- 5
- Details on study design:
- PRE-SCREEN TEST:
In the pre-screen test, 25 μL of the test item (0.5, 1, 2.5, 5 and 10% in MEK) were applied to the dorsum of both ears of two animals, once a day for 3 consecutive days. All animals were observed daily for clinical signs. Body weights were recorded prior to dosing and on the day of necropsy. Furthermore, erythema measurements were performed daily, ear thickness was measured on Day 1 (pre-dose) and Day 3 and 6.
- Compound solubility: The test item was soluble in the vehicle at a concentration of up to 10%.
- Systemic toxicity: No signs of toxicity were observed.
No further informations were given on results of the pre-screen test.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: mouse local lymph node assay (LLNA): BrdU-ELISA
- Criteria used to consider a positive response: A substance is regarded as sensitizer in the LLNA test inducing a Stimulation Index (SI) ≥ 1.6.
TREATMENT PREPARATION AND ADMINISTRATION: Based on the negative results in the pre-screen test, the test item was used at 2.5, 5 and 10% concentration in the main study. 25 μL of each dose formulation were applied to the dorsum of both ears of each animal once a day for 3 consecutive days. Observations took place like described above for the pre-screen test. On Day 5, the animals were injected inter-peritoneally with 0.5 mL/animal of a BrdU solution (10 mg/mL in phosphate buffered saline (PBS)). The animals were sacrificed on Day 6, approximately 24 h after BrdU injection. Using a punch for skin biopsy of 6 mm in diameter the inner tissue of the ear was removed about 1 mm from the outside of the ear and tissues of both sides were weighed together. The draining auricular lymph nodes from each mouse ear were excised and processed separately in PBS for each animal. For each mouse, a single-cell suspension of lymph node cells (LNC) was prepared by #70 nylon mesh to generate a single cell suspension. BrdU was measured by ELISA using a commercial kit (Roche Applied Science, batch no. 24890800), according to manufacturer instructions. Absorbance (OD) was detected at 370 nm (with reference wavelength: 492 nm). - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- Statistical analysis was conducted using a statistical program (version 9.3, SAS Institute Inc., U.S.A.) for the data including body weight, erythema score, ear thickness, ear weight and stimulation index. Bartlett’s test was employed on homogeneity of variance (significance level: 0.05) for body weights, ear thickness, ear weight and stimulation index data. One-way analysis of variance (ANOVA) was employed on homogeneous data. Dunnett’s ttest was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed) between the negative control group and each of the test substance groups or positive control group (G5). Since not significant, Kruskal-Wallis test was employed on heterogeneous data and Steel’s test was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed) between the negative control group and each of the test substance groups or positive control group.
Kruskal-Wallis test for the erythema score was employed on heterogeneous data, and Steel’s test was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed) between the negative control group and each of the test substance groups or positive control group. - Positive control results:
- The positive control substance (25% HCA) induced a positive reaction, determined by a SI of 2.53. Thus, the study was considered as valid.
- Key result
- Parameter:
- SI
- Remarks:
- mean of 5 animals
- Value:
- 1.13
- Test group / Remarks:
- 2.5% test group
- Key result
- Parameter:
- SI
- Remarks:
- mean of 5 animals
- Value:
- 0.76
- Test group / Remarks:
- 5% test group
- Key result
- Parameter:
- SI
- Remarks:
- mean of 5 animals
- Value:
- 0.75
- Test group / Remarks:
- 10% test group
- Parameter:
- SI
- Remarks:
- mean of 5 animals
- Value:
- 2.53
- Test group / Remarks:
- positive control group
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA
: No (significant) increase in lymphoproliferation (SI > 1.6) was observed at all tested concentrations of the test substance.
DETAILS ON STIMULATION INDEX (SI) CALCULATION :
BrdU labelling index = (ABS em – ABS blank em) – (ABS ref – ABS blank ref)
em = Emission wavelength
ref = Reference wavelength
SI = Mean of BrdU labelling index/mouse of test substance/ Mean of BrdU labelling index of negative control
CLINICAL OBSERVATIONS: Neither mortality nor clinical signs were observed in animals treated at all investigated dose levels.
BODY WEIGHTS: No significant changes in body weight were observed during the study.
OTHER OBSERVATIONS:
Erythema: No erythema were observed in the treated animals at any dose or reading time point.
Ear thickness: On Day 6, a significant, but not relevant increase was observed in the highest dose group (10%) when compared to the negative control (Mean ± SD: 0.22 ± 0.0 mm vs. 0.21 ± 0.0 mm (NC), respectively). Except of this, no significant differences when compared to the negative control group.
Ear weight: There were no significant differences when compared to the negative control group. - Interpretation of results:
- other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No. 1272/2008.
Reference
Table 1: Stimulation Indices in mice
Compound |
Concentration [%] |
BrdU labelling Index (Animal No.) |
BrdU labeling Index |
Stimulation Index (SI) |
||||
1 |
2 |
3 |
4 |
5 |
Mean ± SD |
Mean ± SD |
||
Vehicle control (MEK) |
0 |
0.25 |
0.18 |
0.15 |
0.21 |
0.16 |
0.19 ± 0.04 |
1.0 ± 0.21 |
Test substance |
2.5 |
0.27 |
0.2 |
0.17 |
0.18 |
0.26 |
0.21 ± 0.05 |
1.13 ± 0.24 |
5 |
0.19 |
0.13 |
0.03 |
0.15 |
0.21 |
0.14 ± 0.07 |
0.76 ± 0.37 |
|
10 |
0.18 |
0.12 |
0.13 |
0.12 |
0.16 |
0.14 ± 0.03 |
0.75 ± 0.15 |
|
Negative control (HCA) |
25 |
0.49 |
0.52 |
0.45 |
0.51 |
0.43 |
0.48 ± 0.04 |
2.53 ± 0.20 ** |
** = statistically significant increase vs. vehicle control group (p<0.01)
MEK = methyl ethyl ketone
HCA = α-Hexylcinnamaldehyde
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Skin sensitisation in vivo
The skin sensitisation potential of sorbitan tridocosanoate was evaluated in a Local Lymph Node Assay (LLNA) that was performed according to OECD guideline 429 and in compliance with GLP (Riken Vitamin, 2018). Based on the results of a pre-test, the main LLNA was performed with test item formulations of 2.5, 5 and 10%
The test item was dissolved in methyl ethyl ketone and 25 µL each were administered on three consecutive days to the dorsal surface of both ears of 5 female CBA/N mice. A similar constituted group of animals received the solvent or the positive control (25%α-hexyl-cinnamaldehyde). Five days after the first topical application of the test item, solvent or positive control, the animals were injected with 0.5 mL BrdU solution. At terminal sacrifice on Day 6, approx. 24 h after BrdU injection, skin biopsies were taken from both ears and the draining auricular lymph nodes were harvested for preparation of single cell suspensions. Cellular proliferation indicated by BrdU incorporation was quantified by ELISA.
No mortality or clinical signs of toxicity were observed and all animals gained weight as expected. On study Day 6, a significant but not relevant increase in ear thickness was observed at the highest concentration tested (10%). There were no further skin reactions observed.
Stimulation indices (SI values), obtained for the test item were 1.13, 0.76 and 0.75 at 2.5, 5 and 10%, respectively, and were below the criteria of a positive response (SI value > 1.6). The positive control gave a significant response (SI value 2.53) at 25%, confirming the validity of the protocol used for this study.
Under the conditions of the test, sorbitan tridocosanoate is not considered to have a skin sensitising potential.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available data on skin sensitisation do not meet the criteria for classification according to Regulation (EC) No. 1272/2008, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)